SeaStar Medical Holding (ICU) AI Stock Analysis

• Market Cap: $25.57M
• Dividend Yield: N/A
• Average Volume (3M): 3.11M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: 87.87%
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 27,914,597
• 10 Day Avg. Volume: 1,078,116
• 30 Day Avg. Volume: 3,105,544
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: -1.93
• Enterprise Value/Gross Profit: -2.00
• Enterprise Value/Ebitda: 0.10
• 1Y Price Target: $2.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 33 Underperform
• Price Target: ―

SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.

Positive Factors

Commercial and Regulatory Progress

The substantial potential of the SCD and early commercial and regulatory progress support a Buy rating for ICU.

Financial Performance

SeaStar reported 2Q25 results with revenue of $338K, up 13.6% from the previous quarter, and a gross margin of 92.0%, which was above estimates.

Regulatory Achievements

The FDA granted two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy.

Negative Factors

Capital Requirements

ICU will likely require significant capital to fund the trial, pursue regulatory approval, and support parallel development efforts across the SCD platform.

Financial Challenges

ICU reported lower revenue and higher operational expenses than expected, indicating potential financial challenges.

SeaStar Medical Holding Business Overview & Revenue Model

Company Description

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

How the Company Makes Money

SeaStar Medical Holding makes money through the sale and licensing of its Selective Cytopheretic Device (SCD) to hospitals, healthcare providers, and potentially through partnerships with other medical technology companies. Revenue is primarily generated from the commercialization of its patented therapies targeting acute kidney injury and other inflammatory conditions. The company may also derive income from ongoing research and development collaborations and potential future expansions into additional therapeutic areas.

SeaStar Medical Holding Financial Statement Overview

Summary

SeaStar Medical Holding is in a precarious financial position with negative equity and ongoing operational struggles. Despite some revenue growth, the company faces significant profitability challenges and relies heavily on external financing, highlighting potential liquidity risks.

Income Statement

The income statement reveals significant challenges. The company reported its first revenue in 2024, but the gross profit margin is low, and the net profit margin is negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating ongoing operational struggles. Although there is a revenue introduction, past years show no revenue, and the trajectory needs monitoring.

Balance Sheet

The balance sheet shows financial instability with negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, which is a significant concern. Total liabilities exceed total assets, and the equity ratio is negative, suggesting poor financial health and high financial risk.

Cash Flow

Cash flow analysis indicates strained liquidity with no free cash flow and operating cash flow issues. The operating cash flow to net income ratio is negligible, reflecting difficulty in converting revenue to cash. Financing cash flow is positive, indicating reliance on external financing to sustain operations, which is risky if not managed well.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	766.00K	135.00K	0.00	0.00	0.00	0.00
Gross Profit	739.00K	135.00K	0.00	0.00	0.00	0.00
EBITDA	-14.39M	-24.58M	-11.14M	-11.61M	-4.38M	-5.24K
Net Income	-14.67M	-24.83M	-26.23M	-23.01M	-4.60M	-3.28M
Balance Sheet
Total Assets	8.38M	4.66M	3.51M	3.04M	603.00K	2.91M
Cash, Cash Equivalents and Short-Term Investments	6.30M	1.82M	176.00K	47.00K	510.00K	2.81M
Total Debt	0.00	574.00K	9.08M	8.83M	2.62M	83.00K
Total Liabilities	5.04M	6.84M	17.38M	23.80M	76.77M	74.49M
Stockholders Equity	3.34M	-2.18M	-13.87M	-20.76M	-2.82M	-71.58M
Cash Flow
Free Cash Flow	-15.36M	-16.01M	-10.29M	-7.79M	-5.11M	-5.57M
Operating Cash Flow	-15.36M	-16.01M	-10.29M	-7.79M	-5.11M	-5.57M
Investing Cash Flow	0.00	0.00	0.00	0.00	-105.57M	0.00
Financing Cash Flow	20.48M	17.65M	10.41M	7.33M	2.82M	4.89M

SeaStar Medical Holding Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICU, the sentiment is Positive. The current price of 0.92 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.68, and below the 200-day MA of 1.46, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 61.05 is Neutral, neither overbought nor oversold. The STOCH value of 67.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICU.

SeaStar Medical Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADXN	57 Neutral	$13.14M	0.71	-162.42%	―	-82.24%	―
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
PSTV	48 Neutral	$45.26M	―	249.03%	―	-3.49%	27.88%
SNSE	40 Underperform	$10.18M	―	-64.18%	―	―	3.99%
GOVX	34 Underperform	$18.91M	―	-9690.24%	―	1943.07%	80.97%
ICU	33 Underperform	$25.57M	―	1475.93%	―	―	87.87%
ERNA	―	$10.20M	―	-2264.31%	―	―	―

SeaStar Medical Holding Corporate Events

SeaStar Medical Secures $6M Through Equity Agreements

On January 31, 2025, SeaStar Medical Holdings entered a Securities Purchase Agreement with an institutional investor, issuing shares and warrants in both a registered direct offering and a concurrent private placement, expecting gross proceeds of approximately $6 million. The funds are intended for general corporate purposes, potentially impacting its operational capabilities and market strategy by enhancing working capital and capital expenditures.